Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

1(33.3%)

Phase 2

1(33.3%)

Phase 3

1(33.3%)

3Total

Phase 1(1)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03642691Unknown

A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial

Role: lead

NCT02269163Phase 3Completed

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

Role: lead

NCT02690714Phase 2Completed

A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia

Role: lead

NCT03265171Unknown

A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

Role: lead

NCT02312180Phase 1Completed

A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency

Role: lead

All 5 trials loaded